By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Tillotts Pharma AG 

Hauptstrasse 27

Ziefen    4417  Switzerland
Phone: 41-61-935-2626 Fax: 41-61-935 2625


SEARCH JOBS


Industry
Biotechnology






Company News
Tillotts Pharma AG Introduces The New Technology OPTICORE (OPTImized COlonic RElease) For Colonic Targeting Of Active Molecules For The Treatment Of Any Colon Disease 11/21/2016 9:59:59 AM
Tillotts Pharma AG's Parent Company Zeria Pharmaceutical Co., Ltd. Receives Approval For Zentacort 3mg Capsules In Japan 10/6/2016 9:55:11 AM
PendoPharm Inc. To Distribute ENTOCORT (Budesonide) In Canada For Tillotts Pharma AG 9/28/2016 6:53:22 AM
Recipharm AB Establishes Long Term Supply Agreement With Tillotts Pharma AG 8/31/2016 9:39:15 AM
Tillotts Pharma AG Under Agreement To Acquire Global Rights For Entocort (Budesonide) From AstraZeneca PLC (AZN) Outside The U.S. 7/9/2015 9:16:51 AM
Tillotts Pharma AG And Numab AG Announce Exclusive Development And Licensing Agreement For TNF-Alpha Blockers As Drug Candidates For Inflammatory Bowel Disease 6/9/2015 6:22:16 AM
Cancer Prevention Pharmaceuticals, Inc. And Tillotts Pharma AG Sign Licensing Agreement For CPP-1X/Sulindac In Europe And Japan 1/10/2014 9:28:02 AM
Tillotts Pharma AG and MediSafe Partner to Go Beyond the Tablet With UCandME™ Program 10/17/2013 10:01:58 AM
Augurix SA and Tillotts Pharma AG Sign Agreement for the Commercialization of Simtomax(R) for Rapid Diagnosis of Celiac Disease 9/7/2011 11:00:41 AM
Cambrex Corporation (CBM) and Tillotts Pharma AG Enter a Development and Commercialization Agreement for Proprietary 5-ASA-Based Technology 7/6/2011 8:43:41 AM
//-->